Work

A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps5091

Authors: Guru Sonpavde, Andrea Necchi, Shilpa Gupta, Gary D. Steinberg, Juergen Gschwend, Michiel Simon Van Der Heijden, Audrey Richiero, Alexandre Lambert, Bradley Raybold, Srikanth Gajavelli, Dimitrios Zardavas, Matt D. Galsky

Institutions: Dana-Farber Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Cleveland Clinic, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Technical University of Munich, The Netherlands Cancer Institute, Bristol-Myers Squibb (United States), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Bristol-Myers Squibb Canada

OpenAlex ID: W3029622210

Cites:

Cited by: 2

Related to: 10